Learn what regulators are already asking about AI, what quality must mean in this new context, and how organizations can begin building the governance infrastructure.
- The Systems And Choreography Needed For Grade B ATMP Material Transfer
- Rethinking ATMP Assurance When Sterility Timelines, Reality Misalign
- Navigating GMP Biosafety Challenges In ATMP Manufacturing
- Ensuring Quality Of CGT Materials
- Zymeworks Shares Its Design Rationale (And Wins) In Early-Phase ADC Trials
- Ever Wonder What Running A $50B Capital Facilities Project Feels Like?
- Generative AI Can Write The Code, But Who Builds In The Quality?
- From "Live Drug" To Precision Tool: Redefining CAR T Safety
CELL & GENE ARTICLES, APP NOTES, CASE STUDIES, & WHITE PAPERS
-
Physiologix™ Serum Replacement Performance On Mesenchymal Stem Cells
Learn about the effectiveness of a xeno-free serum replacement in mesenchymal stem cell (MSC) culture and its potential to enhance cell growth and reduce variability compared to fetal bovine serum.
-
Partnering With Health Systems: Essential Tips For CGT Commercialization
Successful cell and gene therapy commercialization requires early, detailed manufacturer collaboration with health systems to ensure scalable operations and seamless patient access beyond the clinical trial.
-
Advancing Drug Safety And Improving R&D Productivity With The Liver-Chip S1
Explore how the Emulate Liver-Chip S1 revolutionizes predictive toxicology by mimicking human liver biology, achieving superior sensitivity and specificity.
-
Achieving Titer Increase Up To 4-Fold While Maintaining Product Quality
Discover customizable solutions for antibody manufacturing, as well as services for media optimization, feeding strategy optimization, and format conversion.
-
Enabling The Rapid, Reproducible Manufacturing Of TranspoCART Cells
Learn how an innovative technology streamlines Transpocart cell production, making rapid and consistent manufacturing a reality for cell therapies.
-
Standardizing Cryopreservation For Cell Therapy Supply Chains
Explore how a standardized cryopreservation process is transforming leukapheresis handling by reducing risk and improving quality across the cell therapy supply chain.
-
Automated Sampling Of A Four Vessel Parallel CHO Cell Culture
Learn how automated sampling for parallel bioreactors enables continuous, sterile sample collection from CHO cell cultures, maintaining cell density with reduced manual intervention.
-
Streamline Your AAV Process With A Production Platform
AAVs are reshaping gene therapy, but scaling production introduces complexity. Learn how upstream process optimization can improve yield, consistency, and speed to meet growing demands.
-
Spatial Organization Of The CAR Is Critical For CAR T Cell Function
Explore how advanced single‑cell analysis links CAR localization, cell structure, and functional behavior, offering deeper insight into CAR T cell heterogeneity and performance.
-
hiPSC Aggregate Expansion In Stirred-Tank Bioreactors
Learn about a bioreactor-based Human Induced Pluripotent Stem Cell (hiPSC) expansion workflow with the potential to improve cell therapy applications.
NEWSLETTER ARCHIVE
- 04.08.26 -- Ensuring Quality Of CGT Materials
- 04.07.26 -- Aseptic Insights & Automation
- 04.07.26 -- Rethinking ATMP Assurance When Sterility Timelines, Reality Misalign
- 04.07.26 -- STREAM Edition: Regulatory Flexibility In CGT: Key Shifts And Implications With Monika Swietlicka
- 04.06.26 -- New Podcast Episodes: Regenerative Skin Therapy, Orally Available Biologics, Regulatory Flexibility In CGT, and More
CELL AND GENE CONTENT COLLECTIONS
While there are opportunities to scale, there are also manufacturing gaps, capacity issues, and production timelines that require improvement to do so. And then, of course, there’s cost. Because scale up and scale out are significant to everyone in the sector, we’ve curated insightful editorial that addresses the most important aspects of scalability.
More Content Collections